Phase II trial of oral imatinib in combination with every-three-week intravenous docetaxel in patients with metastatic, hormone- refractory prostate cancer

Leonard Joseph Appleman,David M. Friedland,C. Chaussard,William E. Gooding,T. M. Feinstein,M. Sulecki,Terry Evans,S. Corgnati,H. M. Strausser,Gurkamal S. Chatta

Phase II trial of oral imatinib in combination with every-three-week intravenous docetaxel in patients with metastatic, hormone- refractory prostate cancer

2016

Leonard Joseph Appleman
David M. Friedland
C. Chaussard
William E. Gooding
T. M. Feinstein
M. Sulecki
Terry Evans
S. Corgnati
H. M. Strausser
Gurkamal S. Chatta

15603 Background: Imatinib is a small molecule tyrosine kinase inhibitor specific for Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and c-Kit. Inhibition of PDGFR abrogates pericyte migr...

Keywords:

Pathology
Tyrosine-kinase inhibitor
Cancer research
Imatinib
Growth factor receptor
Hormone refractory prostate cancer
Medicine
Platelet-derived growth factor receptor
Docetaxel
Pericyte
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations